Key facts
- Tessel’s last known valuation is $12.0M (Oct 2024).
- It has raised $6.0M; the latest was Early Stage VC in Mar 2025.
- Notable investors include Endless Frontier Labs, E14 Fund, The Engine, Life Extension Ventures, Sarah Smith Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Tessel
- ·The full record, as it builds
Funding rounds
No funding rounds for Tessel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tessel
Operator of a pharmaceutical development firm intended to research human physiology to discover new drugs. The company specializes in finding targets and making molecules to optimize outcomes in patient-derived tissues, enabling medical professionals to offer advanced drug results to their patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 9
- Website
- tessel.bio/
- Ownership
- Privately Held (backing)
Tessel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tessel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tessel in its N-PORT filings yet. We sweep new filings monthly.